US Imposes 15% Tariff On Swiss Pharma Products

2026-04-03 02:08:20

(MENAFN- Swissinfo) American President Donald Trump has announced tariffs of up to 100% on the import of patented medicines into the US. According to a decree published by the White House on Thursday, a tariff of 15% will apply to Swiss pharmaceutical exports. Select your language

Generated with artificial intelligence. Listening: US imposes 15% tariff on Swiss pharma products This content was published on April 3, 2026 - 10:29 5 minutes Keystone-SDA

Deutsch de USA verhängen hohe Pharma-Zölle – 15-Prozent-Satz für die Schweiz Original Read more: USA verhängen hohe Pharma-Zölle – 15-Prozent-Satz für die Sc

Trump has decided to impose tariffs of up to 100% on patented medicines and their active ingredients, according to the US government's announcement. According to the White House, the aim of the tariffs is to strengthen domestic production and reduce dependence on imports.

“According to the Food and Drug Administration, as of 2025, approximately 53% of patented pharmaceutical products distributed domestically are produced outside the country. The degree of import reliance is significant at the API [active pharmaceutical ingredients] level with only 15% of patented APIs by volume domestically produced for the United States market,” stated the official communiqueExternal link published on Thursday.

+Get the most important news from Switzerland in your inbox

However, for countries with trade agreements with the US – including Switzerland and Liechtenstein – the significantly lower rate of 15% will apply. The measures are to come into force in 120 days for large companies and 180 days for smaller companies. Generics and biosimilars are exempt from customs duties for the time being.
More More Medicine access Drugmakers reassess Europe as Trump overhauls drug-pricing rules
This content was published on Mar 20, 2026 President Trump's drug-pricing overhaul has triggered an earthquake in Europe as drugmakers scramble to protect their bottom lines.
Read more: Drugmakers reassess Europe as Trump overhauls drug-pricing

MENAFN03042026000210011054ID1110940489

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.